


Single Technology Appraisal

Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

Final Stakeholder list


Provisional Consultees	Provisional Commentators (no right to submit or appeal)
CompanyTauRx Therapeutics (hydromethylthionine mesylate)	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation
 Patient/carer groups Alzheimer's Research UK Alzheimer's Society Brain and Spine Foundation Brain Charity Dementia UK Innovations in Dementia Neurological Alliance South Asian Health Foundation Specialised Healthcare Alliance Sue Ryder Healthcare professional groups Association of British Neurologists Association of Directors of Adult Social Services 	 Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association Neurological Alliance of Scotland NHS Confederation Scottish Medicines Consortium Wales Neurological Alliance Welsh Government
 British Geriatrics Society British Neuropathological Society British Neuropsychiatry Association College of Mental Health Pharmacy Institute of Neurology Primary Care and Community Neurology Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Psychiatrists Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	 Welsh Health Specialised Services Committee Comparator companies Accord-UK (donepezil, galantamine, memantine) Aspire Pharma (galantamine) Aurobindo Pharma – Milpharm (donepezil, galantamine) Cipla (donepezil) Dr Reddy's Laboratories (galantamine, memantine, rivastigmine) Eisai (donepezil, lecanemab) Eli Lilly and Company (donanemab) Fontus Health (galantamine) Genus Pharmaceuticals (memantine)

Final stakeholder list for the evaluation of hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] Issue date: July 2024



Provisional Consultees Provisional Commentators (no right to submit or appeal) Others Glenmark Pharmaceuticals Department of Health and Social Care (memantine) NHS England Kent Pharma (rivastigmine) NHS North East and North Cumbria Krka UK (memantine, rivastigmine) **ICB** Lundbeck (memantine) NHS South East London ICB Lupin Healthcare (memantine) UCL Dementia Research Centre Mylan (donepezil, memantine, rivastigmine) Novartis Pharmaceuticals (rivastigmine) Ranbaxy, a Sun Pharmaceutical Company (donepezil) Rosemont Pharmaceuticals (donepezil, memantine, rivastigmine) Sandoz (galantamine, rivastigmine) Takeda (galantamine) Thame Laboratories (galantamine) Zentiva (memantine, galantamine) Relevant research groups Brain Research UK Cochrane Dementia and Cognitive Improvement Cochrane UK Genomics England Institute for Ageing and Health Institute of Neurology MRC Clinical Trials Unit National Hospital for Neurology and Neurosurgery National Institute for Health Research Associated Public Health groups **Public Health Wales UK Health Security Agency**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.



Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.